Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
Breast Cancer Research and Treatment Oct 05, 2017
Vriens BEPJ, et al. - The INTENS study determined whether or not delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improved outcome of breast cancer patients. With respect to the pathologic complete response (pCR) rate, there weere no differences between the two treatment arms, but the sequentially-delivered chemotherapy was shown to be superior to triplet combination chemotherapy in terms of survival, despite a lower cumulative dose per agent.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries